@BioWorld

Biopharma’s trusted news source

 USA
bioworld.com/
Joined April 2009
  • Tweets48.2K
  • Following8.8K
  • Followers38.8K
479Media
Senators: @FTC’s PBM probe has dragged on long enough bioworld.com/articles/734979… #biopharma #regulatory #US

Senators: FTC’s PBM probe has dragged on long enough

It’s been more than four years since the U.S. FTC, at congressional insistence, opened its investigation into pharmacy benefit manager (PBM) practices. The agency needs to wrap it up and release a...

bioworld.com
252
#IPO surge continues with @LyciaTx pricing upsized $317M offering bioworld.com/articles/734857… #immune #biopharma #financing

IPO surge continues with Lycia pricing upsized $317M offering

Lycia Therapeutics Inc. is the latest biopharma to go public this year, pricing an IPO of 17.64 million shares at $18 apiece for gross proceeds of $317.5 million to advance clinical work on its...

bioworld.com
277
Global drug approvals jump 50% as @FDA hits 2026 monthly high bioworld.com/articles/734856… #analysis #biopharma #regulatory

Global drug approvals jump 50% as FDA hits 2026 monthly high

Worldwide biopharma approvals reached 57 in September, up 50% from August’s 38 and coming in as the second-highest monthly total of the year, behind June’s 64. Through the first three quarters of...

bioworld.com
1
2
272
Rare diseases specialist Ambrose acquiring AM-Pharma in €161M deal bioworld.com/articles/734855… #endocrine #biopharma #deal #europe

Rare diseases specialist Ambrose acquiring AM-Pharma in €161M deal

After failing a phase III trial in sepsis-associated kidney injury in 2022, AM-Pharma’s ilofotase alfa has been acquired by Ambrose Healthcare for up to €161 million (US$181 million) and will be...

bioworld.com
295
.@FractylHealth bets it all on Revita therapy to maintain weight loss bioworld.com/articles/734854… #weightloss #obesity #medtech #clinical

Fractyl bets it all on Revita therapy to maintain weight loss

Fractyl Health Inc. is determined to pursue the development of its Revita system despite its battered share price and looming litigation. It is cutting nearly half of its workforce, discontinuing the...

bioworld.com
254
.@STAR_Biotech adjusts its orbit with $200M for preclinical pipeline bioworld.com/articles/734853… #hematologic #immune #biopharma #financing

Star adjusts its orbit with $200M for preclinical pipeline

Following the close of the sale of its Vega Therapeutics Inc. subsidiary to Incyte Inc. for $1.25 billion up-front in July 2026, Star Therapeutics LLC was left with an astronomical amount of cash for...

bioworld.com
237
Daiichi ADC up a tree? #Macrogenics’ could be TOP1 in HN bioworld.com/articles/734852… #cancer #biopharma #clinical #ESMO26

Daiichi ADC up a tree? Macrogenics’ could be TOP1 in HN

“So far, so good” was at least one reaction – though not the market’s – to phase I data uncorked by Macrogenics Inc. at the European Society for Medical Oncology meeting in Madrid, where attendees...

bioworld.com
311
.@GileadSciences expands in I&I with $1.28B Pepstar deal for oral IL-23Ri bioworld.com/articles/734851… #immunology #inflammation #biopharma #deal

Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri

Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology...

bioworld.com
285
Interpath-100: data leak, stock drop, spirited defense by ESMO president (free w/ registration) bioworld.com/articles/734850… @moderna_tx @Merck #cancer #biopharma #clinical #ESMO26

Interpath-100: data leak, stock drop, spirited defense by ESMO president

The 2026 European Society of Medical Oncology (ESMO) 2026 annual meeting kicked off with a bit of drama, as Merck & Co. Inc. and Moderna Inc. released the full data from their Interpath-001 study two...

bioworld.com
250
.@Biohaven rises on FDA acceptance of troriluzole NDA resubmission bioworld.com/articles/734974 #biopharma #neurology

Biohaven rises on FDA acceptance of troriluzole NDA resubmission

Shares of Biohaven Ltd. shot up 25% after the firm disclosed in a U.S. SEC filing that the FDA had accepted for review the NDA resubmission seeking approval of Vyglxia (troriluzole) in spinocerebel...

bioworld.com
3
694
Georgiamune draws Menarini in potential $1.1B preclinical deal bioworld.com/articles/734973 #biopharma #deal #cancer

Georgiamune draws Menarini in potential $1.1B preclinical deal

In its first pharma partnership, Georgiamune Inc. is bringing in $45 million up front in a potential $1.1 billion deal with Menarini Group’s Stemline Therapeutics Inc. subsidiary involving GIM-621, a...

bioworld.com
2
707
.@US_FDA launches #Alzheimer’s initiative as @HHSGov updates national plan bioworld.com/articles/734847 #biopharma

FDA launches Alzheimer’s initiative as HHS updates national plan

As part of the U.S. National Alzheimer’s Project Act, the FDA launched the Neuroscience Advancement and Innovation Nexus Oct. 22 to advance the science, tools and regulatory approaches needed to...

bioworld.com
3
598
Alpha male in HS? @Abbvie phase III data subdue @Avalotx shares bioworld.com/articles/734846 #biopharma #HidradenitisSuppurativa #phaseIII

Alpha male in HS? Abbvie phase III data subdue Avalo shares​

Phase III news from competitor Abbvie Inc. in hidradenitis suppurativa (HS) put a sizeable dent in shares of Avalo Therapeutics Inc. (NASDAQ:AVTX), which ended Oct. 22 at $7.45, a loss of $4.81 or...

bioworld.com
2
478
UK opens national #Alzheimer’s trial to test approved, novel drugs bioworld.com/articles/734843 #biopharma @UKDRI

UK opens national Alzheimer’s trial to test approved, novel drugs

The U.K. is setting up a nationwide randomized, placebo-controlled, double-blind Alzheimer's disease trial, which will test multiple drugs in parallel, assessing the potential for repurposing...

bioworld.com
4
659
Will .@QIAGEN shareholders be tempted by @eqt’s €10.8B offer? (free w/one-time registration) bioworld.com/articles/734842 #medtech #MANDA #diagnostics

Will Qiagen shareholders be tempted by EQT's €10.8B offer?

EQT has signed an agreement to take Qiagen NV private, offering shareholders €46.50 a share in cash, in a deal with an enterprise value of approximately €10.8 billion (US$12.13 billion). Qiagen’s...

bioworld.com
483
Japan backs Nipro’s Stemirac for first full approval under CEA bioworld.com/articles/734845 #biopharma #regenerativemedicine #celltherapy #neurology #approval

Japan backs Nipro’s Stemirac for first full approval under CEA

Japan has backed Nipro Corp.’s Stemirac for full approval, about eight years after the mesenchymal stem cell therapy first won conditional approval in 2018. If approved, Stemirac will become the...

bioworld.com
1
456
#AusBiotech2026: Federated AI tackles drug discovery's data bottleneck bioworld.com/articles/734844 #biopharma #DrugDiscovery #AI #ArtificialIntelligence #AusBiotech2026

Federated AI tackles drug discovery's data bottleneck

The next breakthrough in artificial intelligence-driven drug discovery may depend less on more sophisticated algorithms than on unlocking decades of experimental data held by pharma companies and...

bioworld.com
2
335
UK to accept CE marked medical devices indefinitely bioworld.com/articles/734797 #medtech #CEmarked

UK to accept CE marked medical devices indefinitely

The U.K. government has said that it will continue to accept CE marked medical devices on a long-term basis following a public consultation that received more than 1,000 responses from patients,...

bioworld.com
1
1
2
487
Med-tech M&A value doubles despite 70% drop in acquisitions bioworld.com/articles/734796 #medtech #deals @Medtronic @TelixPharma @ITM_Radiopharma @enovismedtech @ecentialrobot

Med-tech M&A value doubles despite 70% drop in acquisitions

Med-tech M&A activity came to a halt in September 2026, with no transactions closing, marking the first zero-value month in BioWorld’s records going back to 2019. The slowdown followed $1.5 billion...

bioworld.com
3
574
.@Roivant, Priovant targeting #uveitis for next brepocitinib NDA bioworld.com/articles/734792

Roivant, Priovant targeting uveitis for next brepocitinib NDA

Roivant Sciences Ltd.’s plans for broadening the reach of recently approved TYK2/JAK1 inhibitor Lisraya (brepocitinib) got a boost on positive phase III data demonstrating solid efficacy in non-inf...

bioworld.com
1
5
799
Load more